Idiopathic Pulmonary Fibrosis (IPF): Current Perspectives and Future Directions
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Respiratory Medicine".
Deadline for manuscript submissions: 20 January 2026 | Viewed by 461
Special Issue Editor
2. Unit of Respiratory Medicine “L. Vanvitelli”, A.O. dei Colli, Monaldi Hospital, 80131 Naples, Italy
Interests: interstitial lung diseases; lung cancer; idiopathic pulmonary fibrosis; chronic respiratory disorders
Special Issue Information
Dear Colleagues,
Idiopathic pulmonary fibrosis (IPF) represents a chronic fibrotic pulmonary disease that is characterized by a rapidly progressive decline in lung function and is associated with a poor prognosis, given that the median survival time ranges from 3 to 5 years after diagnosis. The pathogenesis of IPF is undoubtedly complex and only partly understood.
Recent advances have led to the approval of new antifibrotic drugs, pirfenidone and nintedanib, which have led to a remarkable improvement in patient outcomes. However, patients with IPF continue to succumb to severe end-stage respiratory failure.
For this Special Issue, we are seeking original research and review articles focusing on current perspectives and future directions in the field of IPF, from its pathogenesis to future therapeutic approaches. We warmly welcome a broad range of submissions, including original research papers and reviews, exploring the state of the art in this pressing topic.
Dr. Vito D’Agnano
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pulmonary fibrosis
- IPF
- ILD
- antifibrotics
- EMT
- respiratory physiology
- metabolism
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
